1
/
of
0
FDA Drug Approval, N022388, ACUVUE THERAVISION WITH KETOTIFEN
FDA Drug Approval, N022388, ACUVUE THERAVISION WITH KETOTIFEN
Regular price
$149.00 USD
Regular price
Sale price
$149.00 USD
Unit price
/
per
NDA: 022388
Company: JOHNSON JOHNSON VISN
Drug Name: ACUVUE THERAVISION WITH KETOTIFEN
Active Ingredients: KETOTIFEN FUMARATE
Strength: EQ 19MCG BASE
Dosage Form/Route: DRUG-ELUTING CONTACT LENS;OPHTHALMIC
Action Date: 02/25/2022
Marketing Status: Discontinued
Submission Classification: Type 3 - New Dosage Form and Type 4 - New Combination
Company: JOHNSON JOHNSON VISN
Drug Name: ACUVUE THERAVISION WITH KETOTIFEN
Active Ingredients: KETOTIFEN FUMARATE
Strength: EQ 19MCG BASE
Dosage Form/Route: DRUG-ELUTING CONTACT LENS;OPHTHALMIC
Action Date: 02/25/2022
Marketing Status: Discontinued
Submission Classification: Type 3 - New Dosage Form and Type 4 - New Combination
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.
View full details